This dual-action approach is what distinguishes it from earlier weight loss medications that only targeted one pathway
37 Both studies were focused on HFrEF patients
Clinical trials may differ in patient population, baseline weight and BMI, diabetes status, medication dose, treatment duration, nutrition and lifestyle support, dropout rates, side-effect profiles, study design, and whether the data are published, peer-reviewed, or topline results
The company has patent rights to the medications they invented, and those rights extend to the drug compound itself
Most of the customers on the platform are diabetic or pre-diabetic, with high BMI, and qualify for the drug
Supplied as a lyophilised peptide blend for laboratory research